However, the V-15-32 randomized phase III study, which aimed to confirm the noninferiority of gefitinib to docetaxel in regard to OS [12], was carried out in Japan and involved 490 previously treated NSCLC patients unselected by EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.